Legal Representation
Attorney
Patrice P. Jean
USPTO Deadlines
Next Deadline
1810 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-07-09)
Due Date
July 09, 2030
Grace Period Ends
January 09, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
17 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jul 9, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
Jul 9, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Apr 23, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Apr 23, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Apr 3, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Mar 13, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Mar 13, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Mar 13, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Mar 13, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
Mar 13, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Mar 11, 2024 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
Mar 5, 2024 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
Feb 20, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Feb 20, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jun 29, 2023 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
Jun 28, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
May 30, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
biochemical research and development services; medical research and development services; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and/or cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer; consultancy, advisory and/or information services relating to or connected with the aforementioned services
Additional Information
Design Mark
The mark consists of letters spelling ingenOx horizontally with all letters in lower case except for O which is capitalized. The letter g is in a stylized font. There is a molecule shape after letter x.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
042